Circa Group Pty Ltd
Bio21 Molecular Science
& Biotechnology Institute
30 Flemington Road, Parkville
VIC 3010 Australia
Twitter @circagroup

Tony Duncan
Chief Executive Officer

Warwick Raverty
Chief Scientist

c/o Bio 21, Flemington Road

+61 419 303 117

Circa Group is converting waste biomass into advanced biochemical materials.




Simm Design

MELBOURNE, AUSTRALIA – 13 September 2017 – Biotechnology companies Circa Group Pty. Ltd. and Sanoosa Pty. Ltd. have signed a Memorandum of Understanding (MoU) to continue developing molecules showing early-stage promise in inhibiting protein-protein interactions, which play a key role in disease development.
Targeting such protein complexes directly allows for a more specific response and attacks early disease promoting events. 
Circa and Sanoosa have been developing specific molecules for protein-protein interaction inhibition for three years. The MoU commits the companies to collaborate for a further year, allowing them to build on existing research.
Dr. Warwick Raverty, Chief Scientist at Circa Group, said, “This MoU has been agreed due to recent promising signs of the molecule’s performance against this specific target protein, using Sanoosa’s advanced modelling processes and in lab trials.”
Dr. Herbert Treutlein and Dr. Wolfgang Kissel, Co-Founders and Directors at Sanoosa, said, “By signing this MoU, we will continue Sanoosa’s strategy of working on difficult-to-drug targets, using both our accelerated computational molecule discovery and design capabilities.”


Simm Design

YORK, UK – 11 July 2017 – Circa Sustainable Chemicals UK – a subsidiary of Australian biotechnology company Circa Group – has won an Innovate UK grant, which will be used to develop new applications for bio-based solvents. Circa will focus on two biosolvent application areas: polymer dispersions and coatings removal for paint or graffiti.
Aiming to encourage disruptive ideas, grant candidates had to demonstrate new, highly innovative processes, products or services, as well as show significant return on investment. Thanks to the grant, Circa will be identifying current coatings removal and polymer dispersion applications which rely upon a polar aprotic solvent.
After initial studies, a theoretical framework will be developed to predict future solvent performance and identify commercially relevant polymer systems where biosolvent Cyrene® can be applied. Produced by Circa, Cyrene® is a bio-based alternative to polar aprotic solvents which are under regulatory pressure worldwide due to their toxicity. Cyrene® has a unique property set, including viscosity, surface tension and polarities.

Circa will work with the Green Chemistry Centre of Excellence (GCCE) at the University of York, who also helped develop Cyrene®. The work should be completed by June 2018.
By providing funding for small companies, Innovate UK wants to help overcome innovation barriers and speed up delivery of new products. As winners, Circa demonstrated that its work will lead to successful commercialisation and show significant and sustainable growth.
Jeff Eaves, General Manager at Circa Sustainable Chemicals UK, said, “We are thrilled to win this Innovate UK grant, which will increase application opportunities for biosolvents. We were particularly glad that bio-based solutions won an open call competition, confirming the bioeconomy’s potential and helping to boost biomaterials’ share in markets dominated by petro-based products.”


Simm Design

YORK, UK – 15 June 2017 – ReSolve, a €4.3 million EU project focused on replacing traditional, fossil-based solvents, officially launched today. Led by the University of York, the project consortium is comprised of 11 partners from 5 different countries, including Circa Group subsidiary company Circa Sustainable Chemicals UK Ltd.

ReSolve, an abbreviation of ‘Renewable solvents with high performance in applications and improved toxicity profiles’, is a three-year project looking for alternatives to substances categorised as very high concern (SVHC) under European REACH regulation. ReSolve answers the BBI-2016-R06 call on ‘Bio-based alternatives to improve protection of human health and the environment’.

The project is set to demonstrate production of novel alternatives to replace toxic solvents toluene and NMP, create an additional pipeline of bio-based solvents, establish a toxicological safety testing strategy and evaluate possible production processes of the most advanced bio-based solvent candidates, benchmarked against conventional solvents.

Tony Duncan, CEO and co-founder of Circa Group, said, “As producers of biosolvent Cyrene®, we are delighted to participate in a project focused on developing more non-toxic, bio-based alternatives. Our Furacell™ platform is one of two core technical streams which will demonstrate and produce new, renewable solvents for ReSolve. We are looking forward to collaborating with our project partners and we are keen for ReSolve to be a success story which will enable the EU to further promote the benefits of biosolvents.”